Abstract
Duaklir Genuair is a twice-daily dry powder inhaler licensed as maintenance therapy for COPD. Here we present the clinical data relating to its efficacy and adverse events and discuss its place in therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
